Gnanenthiran, Sonali RSonali RGnanenthiranJha, VivekanandVivekanandJhaSalam, AbdulAbdulSalamAtkins, EmilyEmilyAtkinsChow, Clara KClara KChowNelson, Mark RMark RNelsonRakotz, MikeMikeRakotzSchlaich, Markus PMarkus PSchlaichSchutte, Aletta EAletta ESchutteUsherwood, TimTimUsherwoodRodgers, AnthonyAnthonyRodgers2023-06-052023-06-052023-05Journal of Human Hypertension, 2023, 37 (5), pp.422-4240950-9240http://hdl.handle.net/10044/1/104693In a first of its kind assessment in cardiovascular research, we assessed whether pooled cardiovascular expertise could accurately predict efficacy and tolerability for both a novel and an established treatment option. A survey was administered prior to the publication of the QUARTET (A Quadruple UltrA-low-dose tReatment for hypErTension) trial. QUARTET was a multicentre, double-blind, parallel-group, trial that randomised participants to initial treatment with either monotherapy or an ultra-low dose quadruple single pill combination for 12 weeks. Survey participants were asked to predict blood pressure (BP) at 12 weeks and 52 weeks for both groups.© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Blood PressureHumansHypertensionJournal Articlehttps://www.dx.doi.org/10.1038/s41371-023-00816-yhttps://www.nature.com/articles/s41371-023-00816-y1476-5527